Level D· Scientific groundwork from lab and animal studiesAnimal StudyEurope PMCOpen access

GDF15 promotes osteogenic differentiation of human dental pulp stem cells by activating the TGF-β/SMAD signaling pathway

Deng P., Yang B., Huang C., Li Y., Mei Z., Li Y.

Animal Study on Face & Skin, published in J Tissue Eng (2025) — summary generated from the PubMed abstract.

Open my reading list
Level D· Scientific groundwork from lab and animal studiesEvidence level of this study

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

  • Level A · Stronger Clinical Evidence
  • Level B · Emerging clinical evidence with positive signals
  • Level C · Early human research exploring benefits
  • Level D · Scientific groundwork from lab and animal studies
  • Emerging · Emerging topic under active research
Read the A–D evidence level guide

This page is generated from the PubMed record. The Thai description is an automated summary of bibliographic fields and the abstract, not a full translation, and is not medical advice.

Study type
Animal Study
Journal
J Tissue Eng (2025)
Reported sample size
—
Source database
Europe PMC
PMID
40755460
PMCID
PMC12314354
DOI
10.1177/20417314251357752
Citations
2

Abstract (original English)

Mesenchymal stem cell-mediated bone tissue engineering strategies, including human dental pulp stem cells (hDPSCs), represent an effective therapeutic approach for bone defect repair, particularly in maxillofacial bone defects. Growth differentiation factor 15 (GDF15), a multifunctional cytokine, plays a critical role in bone tissue formation and remodeling. This study aims to investigate the effects of GDF15 on the osteogenic differentiation of hDPSCs and elucidate the underlying molecular mechanisms. Our findings demonstrate that GDF15 expression and secretion are upregulated during the osteogenic differentiation of hDPSCs. Both Gdf15 overexpression and recombinant human GDF15 (rhGDF15) treatment significantly enhanced the osteogenic differentiation of hDPSCs, whereas Gdf15 knockdown produced the opposite effect. In vivo experiments demonstrated that hDPSCs treated with rhGDF15 significantly enhanced new bone formation within implants in both nude mouse subcutaneous transplantation and rat calvarial defect models. Proteomic analysis identified significant enrichment of the TGF-β/SMAD signaling pathway. Molecular docking analysis and co-immunoprecipitation demonstrated the direct binding interaction between GDF15 and TGF-βR2. Both in vitro Western blotting and in vivo immunofluorescence assays confirmed pathway activation. Critically, pharmacological inhibition of this pathway

What this study does not prove

  • • This study does not prove SVF is an approved treatment or a replacement for standard care.
  • • This is preclinical work; animal or laboratory results cannot be applied to humans.

Evidence level

Evidence from laboratory and animal studies provides groundwork for understanding mechanisms and potential before human studies continue.

How we grade evidence

Browse all related research

Filter the research library by this study's title keywords, author, or publication year.

Related research